IRIS UniCatt

Chiloiro, Sabrina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.569
AS - Asia 3.733
EU - Europa 2.661
SA - Sud America 924
Continente sconosciuto - Info sul continente non disponibili 210
AF - Africa 109
OC - Oceania 11
AN - Antartide 1
Totale 13.218
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.343
SG - Singapore 1.582
BR - Brasile 748
IT - Italia 744
CN - Cina 742
VN - Vietnam 559
DE - Germania 449
SE - Svezia 324
FR - Francia 266
BD - Bangladesh 181
GB - Regno Unito 141
FI - Finlandia 129
JP - Giappone 125
CA - Canada 110
RU - Federazione Russa 110
IN - India 108
ID - Indonesia 105
IE - Irlanda 105
HK - Hong Kong 94
PL - Polonia 91
AR - Argentina 70
UA - Ucraina 69
MX - Messico 63
NL - Olanda 55
ZA - Sudafrica 40
AT - Austria 39
ES - Italia 31
TR - Turchia 31
IQ - Iraq 30
EC - Ecuador 26
KR - Corea 26
BE - Belgio 24
VE - Venezuela 22
PK - Pakistan 19
SA - Arabia Saudita 18
AE - Emirati Arabi Uniti 16
CO - Colombia 16
EG - Egitto 15
CL - Cile 14
IR - Iran 14
UZ - Uzbekistan 12
MA - Marocco 11
PE - Perù 11
PY - Paraguay 11
CI - Costa d'Avorio 9
JM - Giamaica 9
PT - Portogallo 9
AL - Albania 8
AZ - Azerbaigian 8
HU - Ungheria 8
JO - Giordania 8
KE - Kenya 8
LT - Lituania 8
RO - Romania 8
CH - Svizzera 7
DO - Repubblica Dominicana 7
MY - Malesia 7
PH - Filippine 7
CR - Costa Rica 6
CZ - Repubblica Ceca 6
LK - Sri Lanka 6
MD - Moldavia 6
RS - Serbia 6
TN - Tunisia 6
BS - Bahamas 5
GR - Grecia 5
HN - Honduras 5
KZ - Kazakistan 5
AU - Australia 4
ET - Etiopia 4
IL - Israele 4
NZ - Nuova Zelanda 4
OM - Oman 4
PA - Panama 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AM - Armenia 3
BB - Barbados 3
BG - Bulgaria 3
DZ - Algeria 3
GE - Georgia 3
GT - Guatemala 3
KG - Kirghizistan 3
NP - Nepal 3
SN - Senegal 3
BH - Bahrain 2
BO - Bolivia 2
DK - Danimarca 2
LB - Libano 2
SV - El Salvador 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AO - Angola 1
AQ - Antartide 1
BW - Botswana 1
CG - Congo 1
CU - Cuba 1
EE - Estonia 1
EU - Europa 1
Totale 12.986
Salva come PNG Salva come JPEG
Città #
Singapore 870
San Jose 646
Ashburn 521
Chandler 410
New York 224
Rome 220
Ho Chi Minh City 209
Beijing 169
Los Angeles 164
The Dalles 120
Hanoi 114
Lauterbourg 105
Tokyo 103
Hefei 96
Dublin 92
Milan 89
São Paulo 85
Hong Kong 84
Dallas 81
Warsaw 81
Jakarta 80
St Louis 80
Ann Arbor 78
Chicago 75
Munich 72
Moscow 68
Tukwila 68
Fairfield 67
Frankfurt am Main 65
San Mateo 59
Helsinki 58
Wilmington 56
Santa Clara 53
Boston 49
Buffalo 49
Council Bluffs 45
Houston 45
Bremen 44
Kent 43
Orem 43
Seattle 43
Montreal 42
Cattolica 40
Turku 40
Atlanta 38
Marseille 38
Denver 37
Princeton 35
Boardman 34
Brooklyn 34
London 32
Phoenix 32
Jacksonville 30
Da Nang 29
Rio de Janeiro 29
Nanjing 27
Nuremberg 24
Brussels 23
Haiphong 22
Mexico City 22
Seoul 22
Woodbridge 22
Hyderabad 21
Lappeenranta 21
North Bergen 21
Cambridge 20
Johannesburg 20
Amsterdam 18
Paris 18
Toronto 18
Belo Horizonte 17
Stockholm 17
Shanghai 16
Vienna 16
Chennai 15
Hangzhou 15
Poplar 15
Augusta 14
Guangzhou 14
Hải Dương 14
Las Vegas 14
Redmond 14
Bari 13
Redwood City 13
Baghdad 12
Memphis 12
Mountain View 12
Mumbai 12
Porto Alegre 12
Querétaro 12
Thái Nguyên 12
Ankara 11
Bexley 11
Dearborn 11
Manchester 11
Norwalk 11
Quito 11
Washington 11
Elk Grove Village 10
Goiânia 10
Totale 6.920
Salva come PNG Salva come JPEG
Nome #
Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism. 499
Hypophysitis Outcome and Factors Predicting Responsiveness to Glucocorticoid Therapy: A Prospective and Double-Arm Study. 363
Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries 329
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review 311
Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors 228
Typical and Atypical Pituitary Adenomas: A Single-Center Analysis of Outcome and Prognosis 213
An Overview of Diagnosis of Primary Autoimmune Hypophysitis in a Single Prospective Monocentric Experience 206
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study 177
Temporoparietal Fascia Flap (TPFF) in Extended Endoscopic Transnasal Skull Base Surgery: Clinical Experience and Systematic Literature Review 169
Xanthogranuloma of the sellar region: A rare tumor. Case illustration and literature review 164
Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients. 161
Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study 159
Radically resected pituitary adenomas: prognostic role of Ki67 labeling index in monocentric retrospective series and literature review 154
The Changing Clinical Spectrum of Hypophysitis 153
DIAGNOSIS OF ENDOCRINE DISEASE: Primary Empty Sella: a comprehensive review 151
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 150
Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice 149
Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results From a Pilot Study 148
Pancreas as an Unusual Metastatic Site of Medullary Thyroid Carcinoma: A Case of Very Long-term Follow-up Under Prolonged Treatment with Somatostatin Analogues 145
Pediatric craniopharyngiomas: magnetic resonance imaging assessment for hypothalamus-pituitary axis dysfunction and outcome prediction 143
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. 142
Autoantibody reactivity profile of primary autoimmune hypophysitis patients: preliminary results 139
Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways 138
Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second Line Therapies: A Longitudinal Study 135
CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs 133
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes 130
Hypothalamitis and pituitary atrophy 130
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy 130
Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors. 129
Genes of the “regulation of lymphocyte activation” pathway may influence immune cells infiltration in growth hormone secreting pituitary tumors 127
First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. 127
The Pathogenic RET Val804Met Variant in Acromegaly: A New Clinical Phenotype? 124
SOMATOSTATIN ANALOGUES VS ACTIVE SURVEILLANCE IN SMALL PANCREATIC NEUROENDOCRINE TUMORS 122
Empty sella syndrome: Multiple endocrine disorders. 121
Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy 120
Trouillas's Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 119
Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients 119
Synchronous Bilateral Adrenalectomy in ACTH-dependent Hypercortisolism: Predictors, Biomarkers and Outcomes 119
Gut Microbiota, LADA, and Type 1 Diabetes Mellitus: An Evolving Relationship 116
Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis 116
Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review 116
Upfront Oxaliplatin–Fluoropyrimidine Chemotherapy and Somatostatin Analogues in Advanced Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors 115
Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review 115
Pregnancy in Autoimmune Hypophysitis: Management of a Rare Condition 115
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours 114
The Role of Growth Hormone Receptor Isoforms and Their Effects in Bone Metabolism and Skeletal Fragility 113
Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin? 112
Understanding the effect of acromegaly on the human skeleton. 112
Acromegaly in the elderly patients 112
Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature 111
Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients. 110
Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. 110
Topography and Radiological Variables as Ancillary Parameters for Evaluating Tissue Adherence, Hypothalamic-Pituitary Dysfunction, and Recurrence in Craniopharyngioma: An Integrated Multidisciplinary Overview 110
Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction 109
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant 108
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review 107
The Differential Diagnosis between Pseudo Cushing's Syndrome and True Cushing's Syndrome in a Septic Patient in the Pre-Agonal Phase: A Case Report 106
Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction 106
Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. 104
IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly 103
The multi-biomarker acro-TIME score predicts fg-SRLs response: preliminary results of a retrospective acromegaly cohort 101
Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study 101
Empty sella syndrome: an update 100
Hypophysitis in COVID-19: a systematic review 100
Cytokines and chemokines modulate the growth of pituitary adenoma/neuroendocrine tumors: preliminary results of a monocenter prospective pilot study 99
Trouillas’s Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 98
Artificial Intelligence for Individualized Radiological Dialogue: The Impact of RadioBot on Precision-Driven Medical Practices 98
Clinical management of teratoma, a rare hypothalamic-pituitary neoplasia 97
Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients 96
Cerebrospinal fluid and serum biomarkers in idiopathic intracranial hypertension: A systematic review 93
Acromegaly can be cured by first-line pasireotide treatment? 93
Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment. 93
Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice 92
Second line treatment of acromegaly: Pasireotide or Pegvisomant? 90
The immune microenviroment in somatotropinomas: from biology to personalized and target therapy 89
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 88
De-escalation treatment with pasireotide for acromegaly: a long-term experience 87
Consensus on criteria for acromegaly diagnosis and remission 87
Letter: A Multicenter, Propensity Score- Matched Assessment of Endoscopic Versus Microscopic Approaches in the Management of Pituitary Adenomas 86
Reliability of intraoperative visual evoked potentials (iVEPs) in monitoring visual function during endoscopic transsphenoidal surgery 84
The Role of Testosterone in Spermatogenesis: Lessons From Proteome Profiling of Human Spermatozoa in Testosterone Deficiency 84
GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study 83
Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis 83
Systemic comorbidities of acromegaly in real-life experience: which difference among young and elderly patients? 82
A Toluene-induced Infundibulo-neuro-hypophysitis: Presentation of a New Cause of Hypophysitis Secondary to Toxic Exposure and Review on Toluene Inhalation Endocrine Effects 82
Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience 82
Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life 81
Colon Cancer Presenting as Pituitary Mass and Hypopituitarism: Recognition and Multidisciplinary Approach of a Rare Case 79
The clinicopathological PANOMEN-3 classification predicts pituitary adenoma prognosis: a real-world retrospective single center study of a surgically treated cohort 75
Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study 75
Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences 74
Interpretable Machine Learning-Based Prediction of Intraoperative Cerebrospinal Fluid Leakage in Endoscopic Transsphenoidal Pituitary Surgery: A Pilot Study 73
Endoscopic Transsphenoidal Surgery in Growth-Hormone Pituitary Adenomas (GH PitNETs): Current Indications, Limitations, and the Importance of a Multidisciplinary Approach 70
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours 70
Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly 69
The paradoxical GH response at OGTT does not predict Pasireotide efficacy but matters for glucose metabolism 68
Predictors of residual and recurrent pituitary neuroendocrine tumors: impact of medial cavernous sinus wall invasion and Trouillas grading 68
Lights or shadows, a promising future for positron emission tomography in pituitary tumors: a systematic review 65
Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly 65
Bone safety of dual-release hydrocortisone in patients with hypopituitarism. 65
Totale 12.281
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.345
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.345
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022454 0 11 6 37 76 25 9 85 23 21 54 107
2022/20231.087 132 153 78 190 56 161 61 78 103 19 27 29
2023/2024658 31 121 23 31 35 113 28 10 39 40 85 102
2024/20251.939 37 42 122 81 91 70 38 54 237 193 449 525
2025/20266.997 773 251 483 994 921 348 989 361 380 521 670 306
2026/20271.109 467 642 0 0 0 0 0 0 0 0 0 0
Totale 13.218